Statistics for Thirdline antiretroviral therapy including raltegravir RAL darunavir DRVr andor etravirine ETR is well tolerated and achieves durable virologic suppression over 144 weeks in resourcelimited settings ACTG A5288 strategy trial

Total visits

views
Thirdline antiretroviral therapy including raltegravir RAL darunavir DRVr andor etravirine ETR is well tolerated and achieves durable virologic suppression over 144 weeks in resourcelimited settings ACTG A5288 strategy trial 11

Total visits per month

views
May 2024 0
June 2024 0
July 2024 0
August 2024 0
September 2024 0
October 2024 0
November 2024 0

File Visits

views
Journal.pdf 23

Top country views

views
South Africa 11

Top city views

views
Johannesburg 11